This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Owens & Minor (OMI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 12.50% and 3.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?
by Zacks Equity Research
Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.
Best Value Stocks to Buy for May 9th
by Zacks Equity Research
GTX, PLTK and OMI made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 9, 2023.
Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 155.56% and 4.15%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Misses Q4 Earnings Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of -28.21% and 6.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AdaptHealth Corp. (AHCO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AdaptHealth Corp. (AHCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Owens & Minor (OMI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 5.13% and 3.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Owens & Minor (OMI) Q3 Earnings Expected to Decline
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Owens & Minor (OMI) Q2 Earnings Meet Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Owens & Minor (OMI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Owens & Minor (OMI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor (OMI) stock based on the movements in the options market lately.
Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 24.68% and 3.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is GN Store Nord (GNNDY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.
Earnings Preview: Owens & Minor (OMI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Owens & Minor (OMI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philips' (PHG) Q1 Earnings Down Y/Y on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q1 top- and bottom-line results reflect negative impact of supply chain constraints and consequences of the Respironics field action.
Here's Why You Should Retain Integra (IART) Stock For Now
by Zacks Equity Research
Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.
Here's Why You Should Hold on to Illumina (ILMN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.
Patterson Companies (PDCO) Moves Up 12.5%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) robust segmental performance and strong prospects in the dental space.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.
Here's Why You Should Hold on to Haemonetics (HAE) For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) given the strength in its Hemostasis Management franchise and increased product uptake.